Siegfried Holding AG (0QQO)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 75.18 |
|---|---|
| 52-week range | 65.20 – 101.20 |
| Return, 1 month / 3 months | +3.9% / +5.7% |
| Return, 1 year / 3 years | −7.0% / −88.7% |
| Trend | Below its 200-day average |
| RSI (14) | 66 |
| Volatility (1 year) | 32.4% |
| Worst drawdown (1 year) | -33.2% |
| Average daily value traded | 1.09M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Siegfried Holding AG is a Swiss pharmaceutical manufacturing company based in Zofingen. It works as a contract development and manufacturing partner for drug companies, producing active pharmaceutical ingredients and finished dosage forms such as tablets and sterile products. Its customers include pharmaceutical and biotechnology firms that rely on it to develop and manufacture their medicines. The company also supplies selected pharmaceutical products of its own, serving healthcare markets in Switzerland and abroad.
On this site Siegfried Holding AG appears as a stock on the London Stock Exchange (UK), code 0QQO, with prices in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Siegfried Holding AG (0QQO) trades on the London Stock Exchange in UK. It last closed at GBP 75.18 on 27 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 2,344 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.0% and over the last three months it rose 5.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 34 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.2% | ||
| From 52-week high | -24.8% | ||
| Momentum | 47 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 5.7% | ||
| 6-month return | -3.5% | ||
| 12-month return, skipping the last month | -10.5% | ||
| Stability (higher is calmer) | 49 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.2% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.09M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | +3.9% |
| 3 months | +5.7% |
| 6 months | −3.5% |
| 1 year | −7.0% |
| 3 years | −88.7% |
| 5 years | −91.5% |
Signals
| 50-day / 200-day average | 72.23 / 77.62 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.47 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2026 | GBX 0.0040 |
| 22 Apr 2025 | GBX 0.0380 |
| 3 May 2024 | GBX 0.0360 |
| 9 May 2023 | GBX 0.0340 |
| 30 Jun 2022 | GBX 0.0320 |
| 7 Jul 2021 | GBX 0.0300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.